Vaccine composition
AssigneesChildren's Hospital of Eastern Ontario Research Institute Inc., Ottawa Hospital Research Institute, McMaster University
InventorsDavid F. STOJDL, John Cameron BELL, Brian LICHTY, Jonathan POL
Life of this patent
Estimating the term…
Abstract
There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.
Claims48
A kit for use in inducing an immune response in a mammal, the kit comprising:
- a first virus that expresses a protein comprising an amino acid sequence of SEQ ID NO:
- 1, or a variant thereof, as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal;
- and
- a Maraba MG1 virus encoding a protein comprising an amino acid sequence SEQ ID NO:
- 1, or a variant thereof, as an antigenic protein, the Maraba MG1 virus formulated to induce the immune response in the mammal;
- the first virus being immunologically distinct from the Maraba MG1 virus.
An isolated Maraba MG1 viral particle having a genome that encodes a protein comprising an amino acid sequence of SEQ ID NO:
- 1, or a variant thereof.
A kit for use in inducing an immune response in a mammal, the kit comprising:
- a first virus that expresses a protein comprising an amino acid sequence of SEQ ID NO:
- 7, or a variant thereof, as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal;
- and
- a Maraba MG1 virus encoding a protein comprising an amino acid sequence of SEQ ID NO:
- 7, or a variant thereof, as an antigenic protein, the Maraba MG1 virus formulated to induce the immune response in the mammal;
- the first virus being immunologically distinct from the Maraba MG1 virus.
An isolated Maraba MG1 viral particle having a genome that encodes encodes a protein comprising an amino acid sequence of SEQ ID NO:
- 7, or a variant thereof.
38-65. (canceled)
A heterologous prime-boost vaccine therapy comprising:
- a first virus that expresses a protein comprising an amino acid sequence of SEQ ID NO:
- 1, or a variant thereof, as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal;
- and
- a Maraba MG1 virus encoding a protein comprising an amino acid sequence SEQ ID NO:
- 1, or a variant thereof, as an antigenic protein, the Maraba MG1 virus formulated to induce the immune response in the mammal;
- the first virus being immunologically distinct from the Maraba MG1 virus.
A heterologous prime-boost vaccine therapy comprising:
- a first virus that expresses a protein comprising an amino acid sequence of SEQ ID NO:
- 7, or a variant thereof, as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal;
- and
- a Maraba MG1 virus encoding a protein comprising an amino acid sequence SEQ ID NO:
- 7, or a variant thereof, as an antigenic protein, the Maraba MG1 virus formulated to induce the immune response in the mammal;
- the first virus being immunologically distinct from the Maraba MG1 virus.
Dependencies are inferred from the claim text.